Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

19.26 -1.11 (-5.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 433,998
Open 20.01
Bid (Size) 14.75 (2)
Ask (Size) 19.28 (1)
Prev. Close 20.37
Today's Range 19.15 - 20.01
52wk Range 13.92 - 28.18
Shares Outstanding 80,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 Small Caps That Have Big Upside
If market sentiment stays bullish, small caps with depressed shares prices and valuation could turn into big-time outperformers. 
Via MarketBeat
Topics Economy
Exposures Economy
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace

Performance

YTD
+26.21%
+26.21%
1 Month
+26.21%
+26.21%
3 Month
-7.14%
-7.14%
6 Month
-25.89%
-25.89%
1 Year
-26.74%
-26.74%

More News

Read More
Insiders Selling DocuSign, Adobe And 2 Other Stocks
Via Benzinga
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
Via Benzinga
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Q3 Earnings Fall Short Of Expectations, Lowers Annual Outlook
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
From Myriad Genetics, Inc.
Via Globe NewsWire
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
From Myriad Genetics, Inc.
Via Globe NewsWire
Why Shares of Myriad Genetics Dropped 24% This Week
Via The Motley Fool
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
From Myriad Genetics, Inc.
Via Globe NewsWire
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Via Benzinga
Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Drops Over 200 Points; Crude Oil Rises Sharply
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Myriad Genetics: Q3 Earnings Insights
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.